David graduated from Paris-Saclay University with a PhD in cancerology for his research on apoptosis and differentiation in neuroblastoma.
During its postdoctoral fellowship, he focused on apoptotic signaling of dependence receptor, neogenin function and netrin-1 function in cancer.
Highly qualified in flow cytometry and genome editing, he joined NETRIS Pharma in 2014 as our molecular and cellular platform manager.